136 related articles for article (PubMed ID: 20421565)
41. Oncologists want FDA to rethink REMS.
Goozner M
J Natl Cancer Inst; 2010 Dec; 102(23):1748-9, 1751. PubMed ID: 21088276
[No Abstract] [Full Text] [Related]
42. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents.
Aapro MS; Link H
Oncologist; 2008; 13 Suppl 3():33-6. PubMed ID: 18458123
[TBL] [Abstract][Full Text] [Related]
43. [Recent advances on the use of erythropoietin in oncology].
Spaëth D
Bull Cancer; 2006 May; 93(5):489-93. PubMed ID: 16777627
[TBL] [Abstract][Full Text] [Related]
44. Consensus on the Existence of Functional Erythropoietin Receptors on Cancer Cells.
Bennett CL; Lai SY; Sartor O; Georgantopoulos P; Hrushesky WJ; Henke M; Armitage JO
JAMA Oncol; 2016 Jan; 2(1):134-6. PubMed ID: 26606114
[No Abstract] [Full Text] [Related]
45. Managing anemia: what do we do now?
Neumann ME
Nephrol News Issues; 2007 May; 21(6):50, 52. PubMed ID: 17518123
[No Abstract] [Full Text] [Related]
46. Reevaluating erythropoiesis-stimulating agents.
Kestenbaum B
N Engl J Med; 2010 May; 362(18):1742; author reply 1743-4. PubMed ID: 20445190
[No Abstract] [Full Text] [Related]
47. Biosimilar epoetins.
Macdougall IC
Nephrol Dial Transplant; 2009 May; 24(5):1698-9; author reply 1699-700. PubMed ID: 19366858
[No Abstract] [Full Text] [Related]
48. Clarifying the use of erythropoietic agents.
Smith RE
J Support Oncol; 2004; 2(3):200, 202; author reply 202. PubMed ID: 15328822
[No Abstract] [Full Text] [Related]
49. Every 3 weeks dosing with darbepoetin alfa: A new paradigm in anaemia management.
Vansteenkiste JF
Cancer Treat Rev; 2006; 32 Suppl 2():S11-5. PubMed ID: 16725268
[TBL] [Abstract][Full Text] [Related]
50. Erythropoietin-stimulating agents: new data yield new insights.
Zitella L
Oncology (Williston Park); 2007 Oct; 21(11 Suppl Nurse Ed):36-8. PubMed ID: 18154208
[No Abstract] [Full Text] [Related]
51. Utilizing quality of life as a factor in treatment choices for chemotherapy-induced anemia.
Koopman W; Iakiri S
J Support Oncol; 2005; 3(6 Suppl 4):20-1. PubMed ID: 16355554
[No Abstract] [Full Text] [Related]
52. The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia.
Ben-Hamadi R; Duh MS; Aggarwal J; Henckler A; McKenzie RS; Tak Piech C
Curr Med Res Opin; 2005 Oct; 21(10):1677-82. PubMed ID: 16238908
[TBL] [Abstract][Full Text] [Related]
53. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
Nowrousian MR; Dunst J; Vaupel P
Strahlenther Onkol; 2008 Mar; 184(3):121-36. PubMed ID: 18330508
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of agents to reduce infarct size: it can be quite REVEALing.
Bhatt DL
JAMA; 2011 May; 305(18):1908-9. PubMed ID: 21558525
[No Abstract] [Full Text] [Related]
55. Experts probe safety concerns of anemia drugs. Panelists call for more restrictions.
Young D
Am J Health Syst Pharm; 2007 Jun; 64(12):1244-6. PubMed ID: 17563039
[No Abstract] [Full Text] [Related]
56. Darbepoetin alfa and history of thromboembolic events.
Ferretti G; Felici A; Cognetti F
J Clin Oncol; 2009 Nov; 27(33):e211; author reply e212. PubMed ID: 19858373
[No Abstract] [Full Text] [Related]
57. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression.
Hedley BD; Allan AL; Xenocostas A
Clin Cancer Res; 2011 Oct; 17(20):6373-80. PubMed ID: 21750199
[TBL] [Abstract][Full Text] [Related]
58. Trends in Erythropoiesis-stimulating agent use and blood transfusions for chemotherapy-induced anemia throughout FDA's risk evaluation and mitigation strategy lifecycle.
Vega A; Zhang R; Wong HL; Wernecke M; Alexander M; Feng Y; Lo AC; Lufkin B; Ryan Q; Izem R; MaCurdy TE; Kelman JA; Graham DJ
Pharmacoepidemiol Drug Saf; 2021 May; 30(5):626-635. PubMed ID: 33534188
[TBL] [Abstract][Full Text] [Related]
59. Safety update on erythropoiesis-stimulating agents: trials within and outside the accepted indications.
Gascón P
Oncologist; 2008; 13 Suppl 3():4-10. PubMed ID: 18458118
[TBL] [Abstract][Full Text] [Related]
60. Warning flags for erythropoiesis-stimulating agents and cancer-associated anemia.
Lappin TR; Maxwell AP; Johnston PG
Oncologist; 2007 Apr; 12(4):362-5. PubMed ID: 17470677
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
